The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 27, 2015
Filed:
Aug. 13, 2013
Applicant:
Janssen Pharmaceutica NV, New Brunswick, NJ (US);
Inventors:
Richard Apodaca, La Jolla, CA (US);
J. Guy Breitenbucher, Escondido, CA (US);
Kanaka Pattabiraman, Palo Alto, CA (US);
Mark Seierstad, Escondido, CA (US);
Wei Xiao, San Diego, CA (US);
Assignee:
Janssen Pharmaceutica NV, Beerse, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07D 295/195 (2006.01); C07D 207/335 (2006.01); C07D 209/08 (2006.01); C07D 209/14 (2006.01); C07D 209/82 (2006.01); C07D 211/16 (2006.01); C07D 213/38 (2006.01); C07D 213/61 (2006.01); C07D 213/75 (2006.01); C07D 215/12 (2006.01); C07D 215/18 (2006.01); C07D 239/42 (2006.01); C07D 241/42 (2006.01); C07D 295/215 (2006.01); C07D 307/79 (2006.01); C07D 317/46 (2006.01); C07D 317/58 (2006.01); C07D 319/18 (2006.01); C07D 333/58 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 213/56 (2006.01); C07D 307/81 (2006.01); C07D 319/16 (2006.01); C07D 333/60 (2006.01);
U.S. Cl.
CPC ...
C07D 295/195 (2013.01); C07D 207/335 (2013.01); C07D 209/08 (2013.01); C07D 209/14 (2013.01); C07D 209/82 (2013.01); C07D 211/16 (2013.01); C07D 213/38 (2013.01); C07D 213/56 (2013.01); C07D 213/61 (2013.01); C07D 213/75 (2013.01); C07D 215/12 (2013.01); C07D 215/18 (2013.01); C07D 239/42 (2013.01); C07D 241/42 (2013.01); C07D 295/215 (2013.01); C07D 307/79 (2013.01); C07D 307/81 (2013.01); C07D 317/46 (2013.01); C07D 317/58 (2013.01); C07D 319/16 (2013.01); C07D 319/18 (2013.01); C07D 333/58 (2013.01); C07D 333/60 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01);
Abstract
Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).